Xiayu Rao
Overview
Explore the profile of Xiayu Rao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luo L, Yang P, Mastoraki S, Rao X, Wang Y, Kettner N, et al.
Mol Cancer
. 2025 Feb;
24(1):48.
PMID: 39955556
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) in combination with endocrine therapy are the standard treatment for patients with hormone receptor-positive, HER2-negative metastatic breast cancer (mBC). Despite the efficacy of CDK4/6is,...
2.
Islam S, Gleber-Netto F, Mulcahy C, Glaun M, Srivastava S, Hunt P, et al.
Sci Transl Med
. 2024 Jul;
16(758):eabq5585.
PMID: 39083586
The incidence of human papilloma virus-mediated oropharyngeal squamous cell carcinoma (OPSCC) has increased over the past 40 years, particularly among young individuals with a favorable prognosis; however, current therapy often...
3.
Michikawa C, Gleber-Netto F, Pickering C, Rao X, Wang J, Sikora A, et al.
Oral Oncol
. 2024 Apr;
153:106729.
PMID: 38663156
Background: Extranodal extension (ENE) of lymph node metastasis is one of the most reliable prognostic indicators for patients with locally advanced oral cancer. Although multiple reports have found a close...
4.
Lulla A, Akli S, Karakas C, Caruso J, Warma L, Fowlkes N, et al.
Mol Cancer Ther
. 2023 Oct;
23(4):492-506.
PMID: 37796181
Metastatic disease remains the leading cause of death due to cancer, yet the mechanism(s) of metastasis and its timely detection remain to be elucidated. Neutrophil elastase (NE), a serine protease...
5.
Baruch E, Nagarajan P, Gleber-Netto F, Rao X, Xie T, Akhter S, et al.
Res Sq
. 2023 Jul;
PMID: 37503252
While the nervous system has reciprocal interactions with both cancer and the immune system, little is known about the potential role of tumor associated nerves (TANs) in modulating anti-tumoral immunity....
6.
Navarro-Yepes J, Kettner N, Rao X, Bishop C, Bui T, Wingate H, et al.
Cancer Res
. 2023 Jun;
83(19):3264-3283.
PMID: 37384539
Significance: Palbociclib-resistant breast cancers respond to abemaciclib and express pathway-specific signatures of sensitivity, providing a biomarker-driven therapeutic option for patients with metastatic breast cancer following disease progression on cyclin-dependent kinases...
7.
Yu X, Zhang Y, Xiong S, McDaniel J, Sun C, Chau G, et al.
Proc Natl Acad Sci U S A
. 2022 Nov;
119(45):e2210618119.
PMID: 36322759
Alterations of the tumor suppressor , one of the most common events in cancer, alone are insufficient for tumor development but serve as drivers of transformation. We sought to identify...
8.
Lulla A, Akli S, Karakas C, Ha M, Fowlkes N, Mitani Y, et al.
Oncogenesis
. 2021 May;
10(5):40.
PMID: 33990543
Salivary gland cancers (SGCs) are rare yet aggressive malignancies with significant histological heterogeneity, which has made prediction of prognosis and development of targeted therapies challenging. In majority of patients, local...
9.
Wei S, Meijers W, Axelrod M, Anang N, Screever E, Wescott E, et al.
Cancer Discov
. 2020 Dec;
11(3):614-625.
PMID: 33257470
Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis. Here, we report a robust preclinical mouse model of...
10.
Gleber-Netto F, Neskey D, Costa A, Kataria P, Rao X, Wang J, et al.
Cancer
. 2020 Aug;
126(20):4498-4510.
PMID: 32797678
Background: The treatment of advanced oral squamous cell carcinoma (OSCC) is a clinical challenge because it is unclear which therapeutic approaches are the best for this highly heterogeneous group of...